Verified email-pattern data for Renephra Ltd. is currently limited. You can still use the company insights and contact sections below.
Renephra currently have a £70k EIS investment opportunity for private investors, following an investment of £231k supported by our lead investors Deepbridge Capital and Catapult Ventures to bring us up to £300k. The minimum investment sought is £70k with an overfunding up to £330k.
Find out more at https://capitalcell.co.uk/campaign/renephra/
________
Renephra is a medical device development company developing a ground breaking technology for minimally invasive fluid removal to address the significant problems of fluid overload and chronic oedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinical needs and is an estimated £3billion market worldwide.
- Chronic Oedema is a debilitating and underestimated health problem affecting millions of people, leading to very poor quality of life, complications, frequent hospital admission and high costs of care.
Currently patients' only alternative is physiotherapy, compression bandages or surgical treatment until Renephra finalizes its wearable, unobtrusive and easy-to-use device for controlled fluid removal from the skin.
- Fluid overload is a major and growing problem, for example a major proportion of the 3 million renal failure patients and 26 million with heart failure suffer from fluid overload. Underlined by increasing prevalence of both diseases (8% annually), this is unsustainable and new approaches are needed urgently.
Current solutions to this problem are limited. When diuretics fail, which occurs in up to 30% cases – the only other option is dialysis or ultrafiltration. These severe treatment strategies are not suitable for everyone, is debilitating and costly.
The Renephra patented Fluid Removal Device uses micro-needle technology combined with negative pressure therapy to access and remove excess interstitial fluid from the skin.
Company Details
- Employees
- 1
- Address
- Manchester Science Park, Medtech Centre, Greenheys Building,pencroft Way,united Kingdom
- Phone
- +44 161 667 1089
- in****@****hra.com
- Industry
- Medical Equipment Manufacturing
- Website
- renephra.com
- Keywords
- chronic oedema treatment, peripheral oedema treatment, medical devices, fluid removal, fluid overload, medical devices.
- HQ
- Manchester
Renephra Ltd. Questions
Renephra Ltd.'s helpline number is +44 161 667 1089
Renephra Ltd.'s website is renephra.com
Renephra Ltd.'s LinkedIn profile is https://uk.linkedin.com/company/renephra-ltd-
Renephra Ltd. has
1 employees.
View email and phone details for 1
employees at Renephra Ltd..
Renephra Ltd.'s industry is
Medical Equipment Manufacturing
Renephra Ltd.'s top competitors are
Mlh Physiotherapy & Sports Injury Clinic,
Back To Health Wrexham - Mold - Chester,
Harris & Ross,
Farndon Physiotherapy Ltd,
Bridgegate Physiotherapy Ltd,
Inaphaea Biolabs,
Rebound Physio And Rehabilitation,
Achieve More Training Ltd,
Forme Physiotherapy,
Relive Physiotherapy.
Renephra Ltd.'s support email address is info@renephra.com
Renephra Ltd.'s categories are Medical Equipment Manufacturing
Explore related pages
Related company profiles:
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.